AXIOMX INC
Biotech · Private
High-throughput synthetic biology platform for rapid recombinant antibody discovery and development
- Grants
- $1.3M
- 5 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 22
- 9 granted · 13 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420152016
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Engineering a phosphotyrosyl-tRNA Synthetase | $220,323 | |
| Federal grant | Department of Health and Human Services · Phase I · Vector and strain system for the in vivo conversion of antibody fragments into IgG molecules | $216,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Vector and strain system for the in vivo conversion of antibody fragments into IgG molecules | $216,000 | |
| Federal grant | Department of Health and Human Services · Phase II · A novel pre-defined CDR library for selection of affinity reagents | $29,550 | |
| Federal grant | Department of Health and Human Services · Phase II · A novel pre-defined CDR library for selection of affinity reagents | $627,908 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1939 | Aktis Oncology | — | $175M |
| 1940 | Quotient Ltd | — | $92M |
| 1941 | Myota, Inc. | — | $16M |
| 1942 | AXIOMX INC | — | — |
| 1943 | Sparrow Pharmaceuticals | — | $73M |
| 1944 | Iviva Medical | — | $2.0M |
| 1945 | PanTheryx, Inc. | — | $84M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Methods And Compositions For Producing A Chimeric Polypeptidegranted
- Methods Of Utilizing Recombination For The Identification Of Binding Moietiesgranted
- Methods For The Production Of Libraries For Directed Evolutiongranted
- Methods For The Production Of Libraries For Directed Evolutiongranted
- Methods Of Utilizing Recombination For The Identification Of Binding Moietiesgranted
- Compositions And Methods For The Identification And Isolation Of Cell-membrane Protein Specific Binding Moietiesapplication
- Compositions And Methods For The Identification And Isolation Of Cell-membrane Protein Specific Binding Moietiesgranted
- Methods And Compositions For Producing A Chimeric Polypeptidegranted
- Methods Of Identifying And Validating Affinity Reagentsapplication
- Methods Of Synthesizing Polynucleotidesapplication
- Methods For The Production Of Libraries For Directed Evolutiongranted
- Methods For The Production Of Libraries For Directed Evolutiongranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.